# Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

> **NCT04321993** · PHASE2 · UNKNOWN · sponsor: **Lisa Barrett** · enrollment: 363 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Baricitinib (janus kinase inhibitor)
- **DRUG:** Remdesivir (antiviral) + barictinib (janus kinase inhibitor)
- **DRUG:** Remdesivir (antiviral)
- **DRUG:** Tocilizumab (interleukin 6 inhibitor)

## Key facts

- **NCT ID:** NCT04321993
- **Lead sponsor:** Lisa Barrett
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-17
- **Primary completion:** 2024-04
- **Final completion:** 2024-04
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04321993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04321993, "Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04321993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*